Evidence map›Paper›PMID 37089934›Full record

SynthesisFrontiers in pharmacology2023

Evaluation of clinical trials of ethnomedicine used for the treatment of diabetes: A systematic review.

Gul Rehman Elmi, Kamil Anum, Kalsoom Saleem, Rameesha Fareed, Sobia Noreen, Haiyan Wei, Yongxing Chen, Avirup Chakraborty, Masood Ur Rehman, Shi Liyuan and 2 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Efficacy and Safety ofFoods (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Gul Rehman ElmiHenan Provincial Key Laboratory of Pediatric Hematology, Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Kamil AnumRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Kalsoom SaleemRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Rameesha FareedRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Sobia NoreenDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Haiyan WeiHenan Provincial Key Laboratory of Pediatric Hematology, Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Yongxing ChenHenan Provincial Key Laboratory of Pediatric Hematology, Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Avirup ChakrabortyDepartment of Neurosurgery, University of Florida, Gainesville, FL, United States.
Masood Ur RehmanRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Shi LiyuanInstitute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Muhammad AbbasInstitute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Yongtao DuanHenan Provincial Key Laboratory of Pediatric Hematology, Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Riphah International University · PKZhejiang Shuren University · CNZhengzhou University · CNUniversität Innsbruck · ATUniversity of Florida · USZhengzhou Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a widespread metabolic disorder with a yearly 6.7 million deaths worldwide. Several treatment options are available but with common side effects like weight gain, cardiovascular diseases, neurotoxicity, hepatotoxicity, and nephrotoxicity. Therefore, ethnomedicine is gaining the interest of researchers in the treatment of DM. Ethnomedicine works by preventing intestinal absorption and hepatic production of glucose as well as enhancing glucose uptake in muscles and fatty tissues and increasing insulin secretion. A variety of plants have entered clinical trials but very few have gained approval for use. This current study provides an evaluation of such clinical trials. For this purpose, an extensive literature review was performed from a database using keywords like "ethnomedicine diabetes clinical trial", "clinical trials", "clinical trial in diabetes", "diabetes", "natural products in diabetes", "ethno-pharmacological relevance of natural products in diabetes", etc. Clinical trials of 20 plants and natural products were evaluated based on eligibility criteria. Major limitations associated with these clinical trials were a lack of patient compliance, dose-response relationship, and an evaluation of biomarkers with a small sample size and treatment duration. Measures in terms of strict regulations can be considered to achieve quality clinical trials. A specific goal of this systematic review is to discuss DM treatment through ethnomedicine based on recent clinical trials of the past 7 years.

Indexed as

clinical traildiabetesethnomedicineoutcomesystematic reviewtreatment

Identifiers

PMID37089934
PMCPMC10119392
OpenAlexW4362700598

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.